Similar articles for PMID: 17537621

Year	Number of Results
2004	1
2005	4
2006	2
2007	5
2008	1
2009	5
2010	8
2011	16
2012	7
2013	11
2014	18
2015	10
2016	6
2017	9
2018	10
2019	13
2020	4
2021	2
2022	2
2023	2
2024	0

1

Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients.

Zhang GC, Lin JY, Wang Z, Zhou Q, Xu CR, Zhu JQ, Wang K, Yang XN, Chen G, Yang JJ, Huang YJ, Liao RQ, Wu YL. Zhang GC, et al. Clin Oncol (R Coll Radiol). 2007 Sep;19(7):499-506. doi: 10.1016/j.clon.2007.04.006. Epub 2007 May 29. Clin Oncol (R Coll Radiol). 2007. PMID: 17537621

2

Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).

Otsuka T, Mori M, Yano Y, Uchida J, Nishino K, Kaji R, Hata A, Hattori Y, Urata Y, Kaneda T, Tachihara M, Imamura F, Katakami N, Negoro S, Morita S, Yokota S. Otsuka T, et al. Anticancer Res. 2015 Jul;35(7):3885-91. Anticancer Res. 2015. PMID: 26124334

3

Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.

Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, Riely GJ, Arcila ME, Soo RA, Meyerson M, Eck MJ, Kobayashi SS, Costa DB. Yasuda H, et al. Sci Transl Med. 2013 Dec 18;5(216):216ra177. doi: 10.1126/scitranslmed.3007205. Sci Transl Med. 2013. PMID: 24353160 Free PMC article.

4

Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.

Rossi S, Toschi L, Finocchiaro G, Di Noia V, Bonomi M, Cerchiaro E, Ceresoli GL, Beretta GD, D'Argento E, Santoro A. Rossi S, et al. Clin Lung Cancer. 2019 Mar;20(2):82-87. doi: 10.1016/j.cllc.2018.10.009. Epub 2018 Nov 2. Clin Lung Cancer. 2019. PMID: 30473385

5

Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).

Martínez-Navarro EM, Rebollo J, González-Manzano R, Sureda M, Evgenyeva E, Valenzuela B, Fernández FJ, Forteza J, Brugarolas A. Martínez-Navarro EM, et al. Clin Transl Oncol. 2011 Nov;13(11):812-8. doi: 10.1007/s12094-011-0739-1. Clin Transl Oncol. 2011. PMID: 22082647

6

Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.

Kobayashi S, Canepa HM, Bailey AS, Nakayama S, Yamaguchi N, Goldstein MA, Huberman MS, Costa DB. Kobayashi S, et al. J Thorac Oncol. 2013 Jan;8(1):45-51. doi: 10.1097/JTO.0b013e3182781e35. J Thorac Oncol. 2013. PMID: 23242437 Free PMC article.

7

Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.

Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, Wang X, Duan CJ, Wu NM, Guo ZQ, Liu YX, Liu HN, Wang YY, Wang J. Bai H, et al. J Clin Oncol. 2009 Jun 1;27(16):2653-9. doi: 10.1200/JCO.2008.17.3930. Epub 2009 May 4. J Clin Oncol. 2009. PMID: 19414683 Clinical Trial.

8

[Comparison of clinical outcomes of patients with non-small cell lung cancer harboring different types of epidermal growth factor receptor sensitive mutations after first-line EGFR-TKI treatment].

Liu JJ, Zhang S, Wu CJ, Ma LX, Liu Y, Li H, Cui HX, Cheng Y. Liu JJ, et al. Zhonghua Zhong Liu Za Zhi. 2016 Mar 23;38(3):211-7. doi: 10.3760/cma.j.issn.0253-3766.2016.03.010. Zhonghua Zhong Liu Za Zhi. 2016. PMID: 26988828 Chinese.

9

Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma.

Tsai TH, Wu SG, Chang YL, Wu CT, Tsai MF, Wei PF, Yang CH, Yu CJ, Yang PC, Shih JY. Tsai TH, et al. J Thorac Oncol. 2012 Jun;7(6):993-1000. doi: 10.1097/JTO.0b013e31824cc46b. J Thorac Oncol. 2012. PMID: 22525557 Free article.

10

Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.

Chen HJ, Mok TS, Chen ZH, Guo AL, Zhang XC, Su J, Wu YL. Chen HJ, et al. Pathol Oncol Res. 2009 Dec;15(4):651-8. doi: 10.1007/s12253-009-9167-8. Epub 2009 Apr 21. Pathol Oncol Res. 2009. PMID: 19381876 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

122 results

Results by year